Arvinas ARVN 深 沪
已收盘 10-24 16:00:00 美东时间
9.21
+0.050
+0.55%
华盛通- 最 高9.55
- 今 开9.25
- 成交量 345.94万股
- 最 低 9.09
- 昨 收 9.16
- 总市值 6.76亿
- 52周最高 28.83
- 市盈率 静 --
- 换手率 4.71%
- 52周最低 5.90
- 委 比 -18.96%
- 总股本 7341.76万
- 历史最高 108.465
- 量 比 1.50
- 振 幅 5.02%
- 历史最低 5.90
- 每 手 1
- 风险率 6.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Arvinas announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC conference. ARV-806 targets KRAS G12D, a common oncogene mutation, addressing unmet needs in cancers like pancreatic, colorectal, and lung. The company is advancing this candidate in a Phase 1 trial for patients with advanced solid tumors.
10-22 20:00
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
Arvinas announced Phase 3 VERITAC-2 trial data showing vepdegestrant significantly delays worsening of quality of life, pain, and functioning compared to fulvestrant in ESR1-mutated ER+/HER2- advanced breast cancer patients. Data presented at ESMO 2025 highlight vepdegestrant's potential as a best-in-class therapy for this population. The drug also showed clinical activity in a Phase 2 neoadjuvant trial. Vepdegestrant, developed with Pfizer, has ...
10-20 08:15
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Forecasting The Future: 7 Analyst Projections For Arvinas
In the latest quarter, 7 analysts provided ratings for Arvinas (NASDAQ:ARVN), s...
10-16 06:01
Arvinas And Pfizer To Highlight New Vepdegestrant Data For ESR1-Mutated Advanced Breast Cancer At ESMO 2025
Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial
10-13 19:08
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
<p>Arvinas announced that new patient-reported outcomes (PRO) data for vepdegestrant, a PROTAC estrogen receptor (ER) degrader, will be presented at the ESMO Congress 2025 in Berlin. Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations. The Phase 3 VERITAC-2 trial and Phase 2 TACTIVE-N study will be highlighted, focusing on vepdegestrant's efficacy and tolerability. Vep...
10-13 11:00
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas announced that two presentations on ARV-102, an investigational PROTAC LRRK2 degrader, will be presented at the 2025 MDS Congress in Honolulu. The first presentation will discuss the safety and pharmacokinetics of ARV-102 in healthy participants, while the second presentation will focus on pathway engagement in healthy volunteers and Parkinson's disease patients. ARV-102 is designed to degrade LRRK2, a protein implicated in neurodegenerat...
10-01 11:00
被嫌弃的PROTAC第一人
（来源：氨基观察） 辉瑞会放弃雌激素受体降解剂vepdegestrant吗？ 自3月公布不及预期的三期临床数据以来，vepdegestrant的去留始终是市场...
09-24 10:00
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma announced the appointment of Brent S. Rice as Chief Commercial Officer. With over 25 years of experience in biotech and pharma, Rice will lead commercial efforts for firmonertinib, a potential treatment for EGFR mutant NSCLC, and advance the company's ADC portfolio. Previously, Rice served as CCO at Autolus Therapeutics and held leadership roles at Amgen and Juno Therapeutics, demonstrating success in launching therapies and bu...
09-22 20:05
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
